A federal health advisory panel voted to recommend allowing pharmacies to produce certain injectable peptides, despite warnings from FDA scientists regarding safety and efficacy.
Key facts
- •The advisory panel voted 8-6 to recommend that BPC-157, TB-500, and KPV be added to the FDA's list of substances safe for pharmacy compounding.
- •FDA staff scientists warned that there is little evidence to support the safe medical use of these peptides.
- •The panel included several new members with professional ties to the peptide industry prior to the vote.
- •Health Secretary Robert F. Kennedy Jr. has publicly stated his support for peptides and his desire to reverse FDA restrictions.
- •Medical experts have characterized the current online peptide market as unregulated and potentially hazardous.
A panel of federal health advisers voted on Thursday to recommend that the Food and Drug Administration (FDA) ease restrictions on several peptides, including BPC-157, TB-500, and KPV. The non-binding recommendation suggests removing current barriers that prevent pharmacies from producing these injectable substances. The vote follows the recent addition of several individuals with ties to the peptide industry to the advisory panel.
Panel Vote and Industry Influence
The panel voted 8-6, with one abstention, to include the peptides on the FDA’s list of substances deemed safe for pharmacy compounding. Supporters of the move, including panelist David Pope of Xifin Pharmacy Solutions, argued that the decision empowers patients, physicians, and pharmacists. Critics, however, noted that the panel's composition was altered before the meeting to include over half a dozen members with professional connections to the peptide industry.
Scientific Concerns and Regulatory Outlook
FDA staff scientists provided critical reviews, stating there is insufficient data to confirm the safety or medical efficacy of the chemicals. Dr. Elizabeth Rebello of the University of Texas MD Anderson Center expressed concern that the panel’s recommendation is driven by market demand rather than scientific evidence. While the FDA is not required to follow the panel's advice, the agency typically does so. Health Secretary Robert F. Kennedy Jr. has previously expressed support for peptides and indicated an intent to overturn existing FDA restrictions.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by The Guardian Health.
